Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Seres Therapeutics, Inc.

< Previous 1 2 3 Next >
Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis
From Seres Therapeutics, Inc.
Via Business Wire
Tickers MCRB
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.